Ferrer — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ferrer is a mission-driven, private Spanish pharmaceutical company with a diversified portfolio spanning therapeutics, diagnostics, and vaccines. It is advancing a late-stage clinical pipeline focused on neurological disorders like ALS and Progressive Supranuclear Palsy (PSP), while maintaining a commercial footprint. The company differentiates itself through its strong 'Ferrer for Good' ESG commitment, which is central to its operations and has earned it recognition as one of the World's Most Ethical Companies.

NeurologyRare Diseases

Technology Platform

Collaborative development model focused on small molecule therapeutics for high-need areas, particularly neurology. Expertise in advancing in-licensed or co-developed programs through clinical stages.

Opportunities

The high unmet need in neurological disorders like ALS and PSP presents a major market opportunity for first-in-class or disease-modifying therapies.

Ferrer's strong ESG brand and collaborative model make it an attractive partner for innovative biotechs, providing access to a differentiated pipeline.

Risk Factors

Clinical failure of its lead neurology programs (pridopidine in ALS and its internal PSP candidate) would significantly impact its growth trajectory.

The company also faces intense competition in the neurology space and the perpetual challenge of balancing its social mission with the financial demands of drug development.

Competitive Landscape

Ferrer competes in the crowded and challenging field of neurology, particularly ALS, against large pharma and specialized biotechs. Its differentiation lies not in a unique technology platform, but in its integrated purpose-driven business model and focus on collaborative development for underserved patient populations.

More companies in Small Molecule Drugs →More companies in Spain →